| Description | FEN1-IN-3 is a human flap endonuclease-1 ( hFEN1 ) inhibitor that stabilizes hFEN1 with an EC 50 of 6.8 μM . |
| In vitro | FEN1抑制剂在Cdc4和Mre11a缺陷（这两种缺陷在结直肠癌中常见）的情况下，选择性地抑制结肠癌细胞的增殖。FEN1是一种潜在的化疗增敏剂，对于修复甲基甲磺酸盐引起的烷基化损伤至关重要。在胶质母细胞瘤和结直肠癌细胞中，降低或抑制FEN1可以增加对Temozolomide的敏感性。[1] |
| Target activity | FEN1 (human):6.8 μM(EC50) |
| molecular weight | 284.27 |
| Molecular formula | C15H12N2O4 |
| CAS | 2109805-87-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (175.89 mM), Sonication is recommended. |
| References | 1. Exell JC, et al. Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site. Nat Chem Biol. 2016;12(10):815-821. |